MSH2 Antibody, Clone: [1184CT1.3.2], Mouse, Monoclonal

Catalog Number: NSJ-F52414-0.08ML
Article Name: MSH2 Antibody, Clone: [1184CT1.3.2], Mouse, Monoclonal
Biozol Catalog Number: NSJ-F52414-0.08ML
Supplier Catalog Number: F52414-0.08ML
Alternative Catalog Number: NSJ-F52414-0.08ML
Manufacturer: NSJ Bioreagents
Host: Mouse
Category: Antikörper
Application: ELISA, WB
Species Reactivity: Human
Immunogen: Purified His-tagged protein was used to produced this monoclonal MSH2 antibody.
Component of the post-replicative DNA mismatch repair system (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. When bound, heterodimers bend the DNA helix and shields approximately 20 base pairs. MutS alpha recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion loops up to 13 nucleotides long. After mismatch binding, MutS alpha or beta forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. In melanocytes may modulate both UV-B-induced cell cycle regulation and apoptosis.
Clonality: Monoclonal
Clone Designation: [1184CT1.3.2]
UniProt: P43246
Purity: Purified
Form: In 1X PBS, pH 7.4, with 0.09% sodium azide
Antibody Type: Primary Antibody
Application Dilute: Western blot: 1:2000
Application Notes: Titration of the MSH2 antibody may be required due to differences in protocols and secondary/substrate sensitivity.